TRANSLATING SCIENCE INTO DRUGS
A multi facet approach for an efficient drug discovery process
Lead Discovery Siena is a SME providing tools and expertise to develop drug discovery programs. LDS offers pharmaceutical services for Industry and Academia and has a diversified pipeline of in licensed and proprietary products for oncology and infections therapeutic areas, including rare diseases. Our focus is to foster the design and development of early drug discovery campaigns up to pre-clinical phases.
LDS offers products and expertise in a wide range of therapeutic areas ranging from oncology to infections.
LDS is looking for suitable opportunities to combine experience and resources with other organisations where specific projects may benefit in the form either of collaborations at various phases during the life of a program or through out-licensing of specific small molecules or classes.
Our clients take advantage of our knowledge and competences to expedite their drug discovery programmes.
Services can be accessed as standalone projects or may be integrated as a part of a medicinal chemistry optimization programme to build customized solutions to meet drug discovery needs, from hit identification and follow-up, to lead optimization and back-up identification. Competencies include dealing with pharmaco-kinetics and -dynamics, solubility and permeability issues, toxicity and side effects.
Integrated medicinal chemistry services, including computational chemistry, synthesis, ADME/PK and biological testing to guide and support the design and development of a new potential drug up to pre-clinical phase, through small molecule rational design, pharmacological and physico-chemical profiling.
A wide range of biological services to support drug discovery and optimization programmes including protein production and purification, assay development and validation, target-based and whole-cell HTS and compound profiling, optimization of biologicals (therapeutic proteins) and protein engineering.
Specific expertise in anticancer agent bioconjugation with antibodies, including development of conjugation techniques with custom antibodies, development of attaching mode of custom toxins to antibodies, development of proprietary antibodies bioconjugated with innovative mode of action.